Overview
Dr Gauthier’s particular clinical research interests are in clinical trial design and the longitudinal study of clinical progression of MS. Specifically, she is interested in the application of improved statistical methods to predict disease progression and response to treatment. She has also been actively involved in numerous clinical trials, including phase I, II, and III trials, using novel therapies for the treatment of MS.
Highlights
- 1Scientific reports · 2022
- 2Neurology(R) neuroimmunology & neuroinflammation · 2022
- 3NeuroImage · 2020
Publications
109 publications
Funding
20 grantsView NIH portfolio on RePORTER ↗
Active
9 grants- MPIR01NS134646-03Multi-scale, multi-modal imaging assessment of trajectories of cognitive impairment in Multiple SclerosisNational Institute of Neurological Disorders and Stroke · 2024–2029
- MPIR01NS136864-03Quantification of the innate immune activity within chronic lesions as a novel treatment biomarker in Multiple SclerosisNational Institute of Neurological Disorders and Stroke · 2024–2029
- Co-IR01AI174064-01A1Immune Privilege, CNS Autoimmunity, and Clostridium perfringens Epsilon ToxinNational Institute of Allergy and Infectious Diseases · 2023–2028
- Sub-PIRG-2407-43760Variability Measures in the Assessment of ParamagnetNational Multiple Sclerosis Society · 2025–2028 · via Vanderbilt University Medical Center
- Co-IRG-2512-45549Harboring the Initial Trigger of Multiple SclerosisNational Multiple Sclerosis Society · 2023–2026
- PINMSS 223937-03Establishing the clinical relevance of chronic active MS lesions and quantification of their inflammatory trajectory for a new treatment targetNational Multiple Sclerosis Society · 2022–2026
- KPS10OD034271-01New PET/CT System for Human and Non-human Primate ImagingOffice of the Director, NIH · 2023–2026
- Co-IRR-1602-07671Quantitative MRI of Lesion Iron and Myelin RepairNational Multiple Sclerosis Society · 2016–2025
- Co-INMSS TA-2204-39428Multi-modal neuroimaging and cognitive assessment of females with multiple sclerosis across different stages of menopauseNational Multiple Sclerosis Society · 2023–2025
Completed grants (11)
- KPS10OD027039-01A17T Magnetic Resonance Imaging System for Basic, Translational and Clinical ResearchOffice of the Director, NIH · 2021–2025
- Sub-PIA138740Race to Erase MS Innovation AwardRace to Erase MS · 2021–2024 · via University of California, San Francisco
- PIR01NS104283-05Identifying mechanisms of tissue injury in MS lesions: a multi-modality imaging approachNational Institute of Neurological Disorders and Stroke · 2018–2024
- MPIR01NS105144-05No-Gd MRI for Monitoring Disease Status in Multiple SclerosisNational Institute of Neurological Disorders and Stroke · 2018–2024
- PISRA 202213-01Examination of extracellular vesicles in patients with chronic active MS lesionsMyelin Repair Foundation · 2019–2023Contract
- MPIU24NS107168-05Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT sites)National Institute of Neurological Disorders and Stroke · 2018–2023 · via Columbia University
- Co-IR01NS102267-05Detection, Characterization and Treatment of Chronic Microglial Inflammation in Established MS LesionsNational Institute of Neurological Disorders and Stroke · 2017–2022 · via Yale University
- Co-IR01NS090464-05Multiple Sclerosis Lesion Magnetic Susceptibility ActivityNational Institute of Neurological Disorders and Stroke · 2015–2022
- Co-IR21NS104634-02Quantifying the Role of the Connectome in Resiliency to Multiple SclerosisNational Institute of Neurological Disorders and Stroke · 2017–2021
- KPU01NS082329-01NeuroNEXTNational Institute of Neurological Disorders and Stroke · 2013–2018 · via Harvard Medical School
Clinical research
7 studies
Active
4 studies- PIQuantification of the innate immune activity within chronic lesions as a novel treatment biomarker in Multiple Sclerosis: a PET validation studyWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2026)
- PIWeill Cornell CNS Demyelinating Disorders DatabaseWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2025)
- PIMulti-scale, multi-modal imaging assessment of trajectories of cognitive impairment in Multiple SclerosisWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2024)
- PIQuantification of the innate immune activity within chronic lesions as a novel treatment biomarker in Multiple SclerosisWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2024)
Completed & closed trials (3)
- PINCT06292923A Phase 2a Randomized, Double-Blind, Placebo-Controlled, Multicenter Dose-Ranging Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis PatientsPHASE2 · Tiziana Therapeutics INC · CLOSED TO ACCRUAL (as of 2026)Secondary Progressive Multiple Sclerosis
- PIEvaluating the impact of Ocrelizumab on chronic active MS lesions utilizing quantitative susceptibility mapping and myelin water imaging - BRANYplus TransferWeill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2025)
- PIEvaluation of CNS Derived Extracellular Vesicles in MS Patients with Chronic Active LesionsWeill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2021)
Mentoring
1 menteeAll publications with mentees →
External relationships
Advisory/Scientific Board Member
Novartis Pharmaceuticals Corporation
Other
Novartis Pharmaceuticals Corporation · Regeneron Pharmaceuticals, Inc.